We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biotech Growth Trust (the) Plc | LSE:BIOG | London | Ordinary Share | GB0000385517 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-24.00 | -2.53% | 926.00 | 922.00 | 923.00 | 955.00 | 925.00 | 941.00 | 48,374 | 16:29:55 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | -32.42M | -41.3M | -1.0034 | -9.23 | 381.13M |
TIDMBIOG 18 January 2021 THE BIOTECH GROWTH TRUST PLC (the "Company") Appointment of New Director The Board of The Biotech Growth Trust PLC is pleased to announce the appointment of Dr Nicola Shepherd as an independent non-executive Director of the Company, with effect from 18 January 2021. Dr Shepherd is the founder and a Director of Bellows Consulting Limited which operates in the biomedical translational sector, providing strategic advice and assisting clients in moving their projects closer to the market. Previously Dr Shepherd was a senior member of the Innovations Division at the Wellcome Trust where she was responsible for the establishment, management and oversight of the Translation Fund, a £30M a year investment into new product development covering therapeutics, vaccines, diagnostics, medical devices and regenerative medicine over a range of clinical indications. Working closely with project teams, from academic, not-for-profit and commercial organisations, she provided critical guidance and oversight in steering over 50 funded programmes from basic research towards or into the clinic. Dr Shepherd has also held positions at AstraZeneca in Late-Stage Development and Manufacturing; at Global Prior Art (a patent specialist in intellectual property) based in Boston (US) carrying out competitor analysis, due diligence and prior art searching; and Brown University carrying out post-doctoral research into complex formulations. Dr Shepherd is a Member of the CARB-X Advisory Board (www.carb-x.org), and a reviewer for Innovate UK. The Chairman of The Biotech Growth Trust PLC, Andrew Joy, commented: "My fellow Directors and I are delighted to welcome Dr Shepherd to the Board. We are very pleased to have appointed a Director with extensive and relevant expertise both in the UK and internationally." Dr Shepherd's appointment will be proposed to shareholders for election at the Annual General Meeting of the Company to be held in July 2021. There is no further information to be disclosed under Listing Rule 9.6.13R(2) to (6). - ENDS- For further information please contact: Mark Pope Frostrow Capital LLP Company Secretary 020 3 008 4913 END
(END) Dow Jones Newswires
January 18, 2021 02:01 ET (07:01 GMT)
1 Year Biotech Growth Chart |
1 Month Biotech Growth Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions